Page 2
Over 40 mln doses of Russia’s Sputnik V coronavirus vaccine have been released for public distribution since the medication was registered in the country, Alexander Gitsburg, the Director of the Gamaleya Center, the vaccine developer, told …
The Sputnik V vaccine against coronavirus is effective against all known new strains, Alexander Gintsburg, Director of the Gamaleya National Research Center for Epidemiology and Microbiology that developed the jab, reported. "As …
The trials of the Sputnik V vaccine against the coronavirus infection in children may begin in the next few weeks provided a corresponding permit of the Russian Health Ministry is obtained, Alexander Gintsburg, Director of the Gamaleya National …
Russia may register a nasal vaccine against COVID-19 developed by the Gamaleya Research Center for Epidemiology and Microbiology in 2022, if the clinical trials planned for 2021-2022 are successful, head of the center Alexander Ginzburg said. …
The Sputnik V coronavirus vaccine gives enough antibodies to combat the virus’ Indian strain, director of the Gamaleya Center, the vaccine developer, Alexander Gintsburg said on Tuesday. "If necessary, we will combat the …
It will be possible to vaccinate 70% of Russia’s population against the coronavirus infection by November 2021, director of the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry Alexander …
People vaccinated with Russia’s Sputnik V anti-coronavirus vaccine will certainly not develop long-term after-effects such as cancer, the head of the vaccine’s developer said on Tuesday. "Nucleic acids that are …
Russia’s Sputnik V vaccine may also effectively protect animals from COVID-19, Alexander Gintsburg, the head of the Russian Gamaleya Research Institute of Epidemiology and Microbiology Microbiology that developed the drug, said. …
Russia's Gamaleya research institute will start clinical trials of its antibody-based drug against the coronavirus on people at the end of the year, the medication should help significantly reduce mortality from COVID-19, institute chief …
No fatalities have been reported as of yet among those vaccinated with Sputnik V, the director of the Gamaleya National Research Center for Epidemiology and Microbiology that developed Sputnik V, Alexander Gintsburg, told an online briefing …
A "light" vaccine against the coronavirus, that is, inoculation with only one of the two vaccine components, will protect against the infection for three or four months, Director of the Gamaleya National Research Center for …
Post-registration clinical tests of the anti-coronavirus vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry will begin on September 4 or 5, the Center’s director …
A Covid-19 mass vaccination campaign may start in Russia in December-January, director of the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry Alexander Gintsburg said. "Based …
